183 related articles for article (PubMed ID: 24951338)
1. Cilostazol and outcome in outpatients with peripheral artery disease.
Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
[TBL] [Abstract][Full Text] [Related]
2. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
Lee C; Nelson PR
Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
4. Alcohol consumption and outcome in stable outpatients with peripheral artery disease.
Garcia-Diaz AM; Marchena PJ; Toril J; Arnedo G; Muñoz-Torrero JF; Yeste M; Aguilar E; Monreal M;
J Vasc Surg; 2011 Oct; 54(4):1081-7. PubMed ID: 21684714
[TBL] [Abstract][Full Text] [Related]
5. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes.
Leeper NJ; Bauer-Mehren A; Iyer SV; Lependu P; Olson C; Shah NH
PLoS One; 2013; 8(5):e63499. PubMed ID: 23717437
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
[TBL] [Abstract][Full Text] [Related]
7. Effects of cilostazol on arterial wound healing: a retrospective analysis.
Resnick KA; Gordon IL
Ann Vasc Surg; 2014 Aug; 28(6):1513-21. PubMed ID: 24561209
[TBL] [Abstract][Full Text] [Related]
8. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events.
Kalantzi K; Tentolouris N; Melidonis AJ; Papadaki S; Peroulis M; Amantos KA; Andreopoulos G; Bellos GI; Boutel D; Bristianou M; Chrisis D; Dimitsikoglou NA; Doupis J; Georgopoulou C; Gkintikas SA; Iraklianou S; Kanellas Κ; Kotsa K; Koufakis T; Kouroglou M; Koutsovasilis AG; Lanaras L; Liouri E; Lixouriotis C; Lykoudi A; Mandalaki E; Papageorgiou E; Papanas N; Rigas S; Stamatelatou MI; Triantafyllidis I; Trikkalinou A; Tsouka AN; Zacharopoulou O; Zoupas C; Tsolakis I; Tselepis AD
J Am Heart Assoc; 2021 Jan; 10(1):e018184. PubMed ID: 33327737
[TBL] [Abstract][Full Text] [Related]
10. Raised Fibrinogen Levels and Outcome in Outpatients With Peripheral Artery Disease.
Altes P; Perez P; Esteban C; Sánchez Muñoz-Torrero JF; Aguilar E; García-Díaz AM; Álvarez LR; Jiménez PE; Sahuquillo JC; Monreal M;
Angiology; 2018 Jul; 69(6):507-512. PubMed ID: 29113452
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol: improving walking distance in patients with intermittent claudication.
Collinson DJ; Donnelly R
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol: a new drug in the treatment intermittent claudication.
Kumar M; Bhattacharya V
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
[TBL] [Abstract][Full Text] [Related]
13. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Stone WM; Demaerschalk BM; Fowl RJ; Money SR
J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of cilostazol: a critical review of the literature.
Rogers KC; Oliphant CS; Finks SW
Drugs; 2015 Mar; 75(4):377-95. PubMed ID: 25758742
[TBL] [Abstract][Full Text] [Related]
15. Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Manolis AA; Manolis TA; Melita H; Mikhailidis DP; Manolis AS
J Clin Pharmacol; 2022 Mar; 62(3):320-358. PubMed ID: 34671983
[TBL] [Abstract][Full Text] [Related]
16. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
Farkas K; Kolossváry E; Járai Z
Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
[TBL] [Abstract][Full Text] [Related]
18. Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease.
Bernaudo D; Coll R; Sánchez Muñoz-Torrero JF; Pascual MT; García-Díaz AM; Alvarez LR; Monreal M;
Atherosclerosis; 2013 Jul; 229(1):258-62. PubMed ID: 23714334
[TBL] [Abstract][Full Text] [Related]
19. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
Farkas K; Járai Z; Kolossváry E
Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
[TBL] [Abstract][Full Text] [Related]
20. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
